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Abstract
Human blood monocytes play a central role in dengue infections and form the majority of virus infected cells in the blood.
Human blood monocytes are heterogeneous and divided into CD16
2 and CD16
+ subsets. Monocyte subsets play distinct
roles during disease, but it is not currently known if monocyte subsets differentially contribute to dengue protection and
pathogenesis. Here, we compared the susceptibility and response of the human CD16
2 and CD16
+ blood monocyte subsets
to primary dengue virus in vitro. We found that both monocyte subsets were equally susceptible to dengue virus (DENV2
NGC), and capable of supporting the initial production of new infective virus particles. Both monocyte subsets produced
anti-viral factors, including IFN-a, CXCL10 and TRAIL. However, CD16
+ monocytes were the major producers of inflammatory
cytokines and chemokines in response to dengue virus, including IL-1b, TNF-a, IL-6, CCL2, 3 and 4. The susceptibility of both
monocyte subsets to infection was increased after IL-4 treatment, but this increase was more profound for the CD16
+
monocyte subset, particularly at early time points after virus exposure. These findings reveal the differential role that
monocyte subsets might play during dengue disease.
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Introduction
The human peripheral blood monocyte population can be
divided into two distinct subsets based on CD16 expression [1,2].
Under healthy physiological conditions, the CD16
2 monocyte
population comprises of approximately 90% of total monocytes,
while the remaining 10% consist of CD16
+ monocytes. CD16
2
monocytes are predisposed to produce IL-10, while CD16
+
monocytes produce more pro-inflammatory cytokines, for exam-
ple TNF-a [3,4]. CD16
2 express CCR2 while CD16
+ monocytes
preferentially express CX3CR1 [5], and exhibit different move-
ment and migratory behaviors [629]. Monocyte subsets are
known to play different roles during disease conditions. For
example, CD16
+ monocytes are elevated during several inflam-
matory and infectious conditions, and have been proposed to play
pro-inflammatory roles during diseases [10]. The CD16
+ mono-
cyte subset has also been shown to be more permissive to HIV
infection [11].
Dengue virus is a single stranded positive sense RNA virus that
belongs to the family Flaviviridae. Dengue virus exists as four
serotypes, DENV-1 to 4 and is transmitted to humans via the bite
of an Aedes mosquito [12,13]. Infection with dengue is asymptom-
atic in the majority of cases [14217], but it may also cause dengue
fever, a debilitating flu-like illness that lasts for up to two weeks. In
rare cases, infection results in dengue hemorrhagic fever or dengue
shock syndrome, severe life threatening diseases characterized by
high fever with vascular leakage and hemorrhage [18,19]. The
incidence of dengue has risen considerably over the recent decade
and it is now a major public health problem [20].
Monocytes are natural host cells for dengue virus [21,22].
Monocytes have been implicated in both pathogenesis and
protection of dengue. Monocytes can produce IFN-a in response
to dengue virus [23]. The depletion of monocytes in a murine
model of dengue infection resulted in a tenfold increase in systemic
viral titers, demonstrating the important role for monocytes in
systemic viral control [24]. On the other hand, monocytes
promote dengue pathogenesis by being the primary vessels of
virus propagation [25,26]. During secondary immune responses,
monocyte infection could be facilitated through antibody depen-
dent enhancement, leading to increased infected cell numbers and
higher viral load [27,28]. Monocytes/macrophages can produce
cytokines and chemokines that compromise the integrity of the
endothelial cell layer [29233], possibly leading to vascular
leakage, the hallmark of severe dengue disease [18,27]. Increased
numbers of CD16
+ activated monocytes were found in dengue
patients [34].
Evidence suggests that severe manifestations of dengue could be
caused by an inappropriate Th2-biased immune response. For
example, levels of IL-13 are elevated in patients with dengue
hemorrhagic fever [35]. Gene expression profiling of blood cells of
children with dengue shock syndrome showed increased tran-
scripts of anti-inflammatory and repair/remodeling genes [36],
which happens through the ‘‘alternative’’ activation of monocytes
with Th2 cytokines. In vitro, pre-treatment of human primary
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enhanced susceptibility to dengue virus [37] through the increased
expression of dengue virus binding receptors, DC-SIGN (CD209)
[38] and mannose receptor (CD206) [37].
Given the vital role of monocytes in dengue virus infection, it is
important to delineate how monocyte subsets could differently
support dengue virus replication and contribute to the protective
and pathogenic manifestations of dengue. In order to investigate
the differential roles of monocyte subsets in a primary dengue virus
infection setting, we isolated the CD16
+ and CD16
2 human blood
monocyte subsets from healthy donors and exposed them to
dengue virus (DENV2 NGC) in vitro. Our results revealed that
both monocyte subsets are similarly susceptible to dengue virus
infection. The two monocyte subsets were also able to effectively
produce protective anti-viral soluble factors. However, monocyte
subsets differed in the production of inflammatory soluble factors
associated with dengue pathogenesis and inflammation. Under
Th2 conditions mimicked by IL-4 treatment, the susceptibility of
monocyte subsets was enhanced, but this affected the CD16
+
monocyte more than the CD16
2 monocyte subset. The results
herein reveal that monocyte subsets can have similar susceptibility
and protective mechanisms against dengue, but may fundamen-
tally differ in the mechanisms of dengue pathogenesis.
Materials and Methods
Isolation of Human Blood Monocyte Subsets
All blood samples and procedures in this study were approved
by the National University of Singapore Institutional Review
Board, approval number NUS 1076, in accordance to guidelines
of the Health Sciences Authority of Singapore. Informed written
consent was taken by the staff of the blood bank of the Health
Science Authority of Singapore, in accordance to the Declaration
of Helsinki. Peripheral blood mononuclear cells (PBMCs) were
obtained from blood of healthy donors using Ficoll-Hypaque (GE
Healthcare, Singapore) density gradient centrifugation at 12006g
for 30 mins at room temperature. CD16
2 and CD16
+ monocyte
subsets were isolated using the CD16 monocyte isolation kit
(Miltenyi Biotec, Singapore) according to the manufacturer’s
instructions, with some modifications. Briefly, NK cells, neutro-
phils and T cells were depleted using microbeads conjugated to
anti-CD56, anti-CD15 and anti-CD3 antibodies. After depletion,
CD16
+ monocytes were isolated using anti-CD16 conjugated
microbeads. CD16
2 monocytes were subsequently isolated from
the negative fraction using anti-CD14 conjugated microbeads.
The purity of the isolated monocyte subsets was consistently
.90%.
Infection of Cells with Dengue Virus
Following isolation, monocytes were exposed to DENV2 NGC
at a multiplicity of infection (MOI) of 10. After 3 h, monocyte
subsets were washed twice and cultured in 96 well U-bottomed
plates at 2610
5 cells per well in 200 ml of RPMI 1640 medium
(Invitrogen, Gibco, Singapore) supplemented with 100 mg/
100 U/ml Streptomycin/Penicillin (Sigma-Aldrich) and 10%
Fetal bovine serum (FBS) (Gibco). All cells were cultured in a
37uC5 %C O 2 incubator. For protection assays, K562 cells
(ATCC, Manassas, VA) were pre-treated for 24 h with superna-
tants from monocyte subsets with or without dengue virus
exposure. Prior to pre-treatment, these supernatants were filtered
through 100 kDa centrifuge filters (Millipore, Billerica, MA) at
30006g, 45 mins at room temperature, to remove virus by size
exclusion. Pre-treated K562 cells were washed and infected with
DENV2 NGC at a MOI of 2. After 1 h, cells were washed and
cultured in RPMI 1640 media with 10% FBS. After 2 days, the
extent of infection was determined by flow cytometry using anti-
NS1 (Non-structural protein 1) intracellular labeling. Data were
collected on a BD FACS calibur (BD Bioscience, CA, San Jose).
Propagation of Dengue Virus
DENV 2 NGC was used for this study. For virus propagation,
C6/36 cells were initially exposed to the virus at MOI of 0.01.
After 1 h, the cells were washed and cultured at 28uC in RPMI
1640 supplemented with 5% FBS. At days 4, 5 and 6, cell
supernatants were harvested. Cell debris was removed by
centrifugation at 10006g for 10 mins and stored at 280uC. Virus
titers were determined by plaque assay.
Plaque Assay
BHK-21 (ATCC, Manassas, VA) cells were seeded into 24 well
plates and grown to confluence. Serially diluted supernatants
containing dengue virus were added to the cells and incubated for
1 h at 37uC in a 5% CO2 incubator. Cells were then overlaid with
RPMI medium containing 0.4% carboxymethylcellulose (Merck
Calbiochem) and incubated for 4 1/2 days at 37uC in a 5% CO2
incubator. The cells were then fixed with 1% formalin before
plaques were revealed by staining with 1% crystal violet (Merck
Calbiochem). Virus titres are thus expressed as plaque forming
units per milliliter (PFU/ml).
Cytokine and Chemokine Detection
The concentrations of cytokines and chemokines reported in
this study were determined using multiplex bead arrays kits (Bio-
Plex Pro Human Cytokine 27 and 21 plex kits) (Biorad, Hercules,
CA) according to the manufacturer’s instructions. Plates were read
using a Luminex 200 (Qiagen, Valencia, CA). IFN-a levels were
determined using IFN-a multi-subtype ELISA kit according to the
manufacturer’s instructions (PBL Interferon Source, Piscataway,
NJ). Absorbance at OD450 nm was measured by a Tecan M200
microplate reader (Ma ¨nnedorf, Switzerland).
Detection of Intracellular Antigens by Flow Cytometry
Cells were fixed with PBS containing 4% paraformaldehyde
(Sigma-Aldrich) for 20 min at room temperature, before permea-
bilization with PBS containing 0.5% BSA and 0.1% saponin
(Sigma-Aldrich). Cells were labeled with anti-NS1 PE (a kind gift
of Dr. Dennis Burton, The Scripps Research Institute, La Jolla,
USA) and anti-E-protein (Envelope protein) (4G2) allophycocya-
nin (ATCC, Manassas, VA) for 45 mins at room temperature.
Following washing with permeabilization buffer the cells were
analyzed using a FACS Calibur (BD Bioscience).
Viability Assays
For Annexin V and 7-AAD (7-Aminoactinomycin D) staining,
cells were washed and resuspended in Annexin V buffer
containing 140 nM NaCl, 2.5 mM CaCl2 and 10 mM Hepes/
NaOH. Cells were subsequently stained with Annexin-V PE (BD
Bioscience) and 7-AAD (eBioscience, San Diego, CA) for 15 min
and analysed by flow cytometry. Live and dead cells were also
discriminated using a Live/DeadH cell stain kit (Invitrogen)
comprising a far red reactive dye with an emission of 660 nm.
Live cells actively exclude this dye and stain dimly, while dead cells
are unable to exclude the dye and stain brightly. Staining was
performed in PBS according to the manufacturer’s protocol,
before analysis by flow cytometry. A MTS assay which detects the
dehydrogenase activity of metabolically active cells was performed
using CellTiter 96H AQueous kit (Promega, Singapore) according to
Monocyte Subsets and Dengue
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MTS into a formazan product was measured by its absorbance at
OD490 nm using a Tecan M200 microplate reader. Absorbance
at OD490 nm is directly proportional to the number of viable cells
in culture.
IL-4 Pretreatment of Monocyte Subsets
Isolated monocyte subsets were seeded into flat-bottom 6-well
plates at a cell density of 1610
6 cells/ml. Monocyte subsets were
treated with recombinant human IL-4 (Immunotools) at concen-
tration of 25 ng/ml. As controls, monocyte subsets were cultured
without IL-4 treatment. The cells were incubated at 37uC, 5%
CO2 for 2 days. The monocyte subsets were washed with culture
media prior to exposure to dengue virus at a MOI of 10.
Statistical Analysis
The statistical significance of the results was determined by a
two-tailed Student’s t test. Differences with p,0.05 were
considered significant.
Results
CD16
2 and CD16
+ Monocyte Populations are Equally
Susceptible to Dengue Virus Infection
We first compared the susceptibility of CD16
2 and CD16
+
monocyte subsets to dengue virus infection. CD16
2 and CD16
+
monocytes were isolated from PBMCs of healthy blood donors.
Typical purities of the isolated monocyte subsets are shown in
Fig. 1 A. Freshly isolated monocyte subsets were subsequently
exposed to dengue virus (DENV2, NGC strain) at a MOI of 10. A
relatively high MOI of 10 was chosen because it consistently gave
results that we detectable by intracellular staining. Infected cells
were identified by intracellular labeling with antibodies specific for
NS1 and E-protein of dengue virus. NS1 is a non-structural
protein that is required for virus replication, whereas E-protein is a
structural protein that is required to package RNA into new virus
particles to be released from infected cells [39]. Using intracellular
flow cytometry analysis, NS1 and E-protein were detected in
monocytes that were exposed to dengue virus but not controls
without virus (Fig 1 B). NS1 and E-protein expression was followed
over a course of six days (Fig. 1 C & D). The percentages of NS1 or
E-protein positive cells were similar for both CD16
+ and CD16
2
monocytes after virus exposure. These results show that both
monocyte subsets were equally susceptible to dengue virus
infection.
We next determined whether both monocyte subsets had the
ability to support production of infectious virus particles. The
supernatants of virus exposed monocyte subsets were harvested
over the course of six days and tested for the presence of newly
produced infective virus by plaque assay on BHK-21 cells (Fig. 1
E). At day 1 post infection, relatively low amounts of infective virus
were detected. Subsequently, the amount of virus produced
increased dramatically, which peaked at day 2. This then rapidly
declined to almost undetectable levels by day 5. Both monocyte
subsets supported the production of infective virus to a similar
extent and with similar kinetics.
Soluble Factors Associated with Protection Against
Dengue are Produced by Both Monocyte Subsets
Cytokines and chemokines produced by monocytes play vital
roles in dengue pathogenesis and protection [29233]. We were
interested to understand if cytokines and chemokines that play a
key role in dengue were differentially produced by monocyte
subsets. Using multiplex bead arrays and ELISAs, we observed
that cytokines and chemokines associated with protection against
dengue, namely CXCL10 [40,41], IFN-a [42,43] and TRAIL
[44] are produced by both monocyte subsets in response to dengue
virus (Fig. 2 A, B, C). Interestingly, the production of these three
soluble factors increased steadily over the course of 6 days in both
monocyte subsets. These factors were present at much higher
levels after the peak of new infective virus production at day 2,
however there was no significant difference between the levels of
these factors in CD16
+ and CD16
2 virus exposed monocytes.
Hence, both monocyte subsets were equally capable of producing
protective factors against dengue virus, although the major part of
this response occurred late (.4 days) after exposure to virus.
Next, we determined the ability of virus exposed monocyte
subsets to confer protection against dengue virus infection.
Supernatants of monocyte subsets 6 days after infection were
used, since they contained the highest levels of factors associated
with protection against dengue. Residual virus in these superna-
tants was first removed by size exclusion using 100 kDa centrifuge
filters. This efficiently reduces infective virus loads by 10
5 fold, but
retains the levels of soluble factors by .80% (data not shown). For
infection, we used K562 cells which are highly susceptible to
infection by dengue virus [43]. K562 cells were pre-treated
overnight with filtered supernatants from day 6 virus exposed
monocyte subsets, non-exposed monocyte subset control superna-
tants or medium only. Pre-treated K562 cells were subsequently
washed and exposed to dengue virus at a MOI of 2. After 2 days,
the levels of intracellular NS1 were determined (Fig. 2 D). We
observed that the percentage of NS1 positive K562 was three fold
lower in cells that had been pre-treated with supernatants of virus
exposed monocytes, as compared to K562 cells pre-treated with
control monocyte supernatants or medium only. This showed that
the supernatants of virus exposed monocytes could significantly
reduce the extent of dengue virus infection of K562 cells. When
comparing CD16
2 and CD16
+ monocytes, no significant differ-
ence in the reduction of K562 infection was observed. Hence,
monocyte subsets infected with dengue virus produced protective
factors, including IFN-alpha and IP-10. Hence, we speculate that
these protective factors present in supernatants used to treat K562
cells protected them from infection by dengue virus.
Inflammatory Cytokines and Chemokines are
Predominantly Produced by CD16
+ Monocytes
In contrast to the soluble factors associated with dengue
protection, differences were observed with the production of
inflammatory cytokines. The levels of IL-1b, IL-6 and TNF-a
produced by CD16
+ monocytes were significantly higher than that
of CD16
2 monocytes in response to dengue virus. Virus exposed
CD16
+ monocytes produced picogram levels of IL-1b and TNF-a,
but these cytokines were undetectable with CD16
2 monocytes
(Fig. 3 A & B). Furthermore, the level of IL-6 produced by CD16
+
monocytes was more than 30 times higher than the levels observed
with CD16
2 monocytes at day 2 (1939.96717.2 versus
58.1621.0) (Fig. 3 C). Hence, CD16
+ monocytes are the major
producers of inflammatory cytokines in response to dengue virus.
The production of CC chemokines, in particular CCL2 (MCP-
1), CCL3 (MIP-1a) and CCL4 (MIP-1b), was also clearly different
between CD16
+ and CD16
2 monocytes. The levels of CCL2, 3
and 4 were significantly higher in supernatants of virus exposed
CD16
+ monocytes compared to virus exposed CD16
2 monocytes.
The level of CCL2 was more than five fold higher for virus
exposed CD16
+ versus CD16
2 monocytes at any time tested (Fig. 3
D). While the level of CCL3 from virus exposed CD16
+ monocytes
was 153.1656.7 pg/ml at day 1, it was barely detectable in
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2 and CD16
+ monocytes after
isolation. (B) Isolated CD16
2 or CD16
+ monocyte subsets were either exposed to dengue virus (DENV2, NGC) at a MOI of 10 or medium without virus.
After 2 days, monocytes were fixed, permeabilized and labeled with anti-E-protein and anti-NS1 specific antibodies. Quadrants for virus exposed
monocytes (right panel) were set based on monocytes without virus exposure (left panel). Percentage positive cells in each quadrant are shown.
Representative data for 6 different donors. (C and D) Percentages of CD16
2 and CD16
+ monocytes that are NS1
+ or E-protein
+ over the course of 6
days after virus exposure. Results are mean 6 SE of 6 different donors. (E) Plaque assays with BHK-21 cells were performed with supernatants taken
from virus exposed CD16
2 or CD16
+ monocytes over the course of 6 days. Results are mean 6 SE from 5 different donors.
doi:10.1371/journal.pone.0036435.g001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36435Figure 2. Production of soluble factors associated with protection against dengue by monocyte subsets. Isolated monocyte subsets
were either exposed to dengue virus (DENV2, NGC) at a MOI of 10 or medium without virus. Supernatants were harvested over the course of 6 days.
(A) Levels of IFN-a were determined by a multi-subtype specific ELISA kit. (B and C) Levels of CXCL10 and TRAIL were determined using multiplex
bead arrays. Results are mean 6 SE for 6 different donors. There were no significant differences were found between infected CD16
2 and CD16
+
monocytes. (D) Supernatants from CD16
2 and CD16
+ monocytes exposed to dengue virus or medium without virus were harvested at day 6. These
supernatants were passed through 100 kDa centrifuge filters to remove dengue virus. K562 cells were pretreated for 24 hours with either culture
medium, supernatants of CD16
2 or CD16
+ monocytes with or without virus exposure. Pre-treated K562 cells were washed and infected with dengue
virus at a MOI of 2. After 2 days, the extent of infection was determined by intracellular labeling of K562 cells with anti-NS1 antibody. The percentage
of NS1
+ K562 cells after 2 days is shown. Data are representative of 2 experiments using different donors. **, p,0.005 between respective monocyte
subset with and without virus.
doi:10.1371/journal.pone.0036435.g002
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36435Figure 3. Production of inflammatory cytokines by monocyte subsets. Monocyte subsets were exposed to dengue virus or medium without
virus. Supernatants were harvested over the course of 6 days. Levels of (A) IL-1b (B) TNF-a (C) IL-6 (D) CCL2 (E) CCL3 and (F) CCL4 were measured
using multiplex bead arrays. Results are mean 6 SE of 5 different donors. * p,0.05, **, p,0.005 between CD16
+ and CD16
2 monocytes with virus.
doi:10.1371/journal.pone.0036435.g003
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2 monocyte cultures (Fig. 3 E). Similarly, CCL4 production
was 40 fold higher in CD16
+ monocytes than CD16
2 monocytes
at day 1 (2295067221 pg/ml vs 5706195) (Fig. 3 F). The
production of CCL3 and CCL4 by virus exposed CD16
+
monocytes was transient, and rapidly declined after day 1.
However, the levels of CCL2 remained relatively constant over
6 days after virus exposure.
Viability of Both Monocyte Subsets is Enhanced after
Exposure to Dengue Virus
Through flow cytometry analysis, we noted differences between
the scatter profiles of monocytes that were exposed to dengue virus
compared to monocytes without virus. For example at day 2,
monocyte subsets without virus consist of a higher percentage of
cells with a lower forward scatter and higher side scatter (Fig. 4 A),
a profile typical of dead cells. In contrast, dengue virus exposed
monocytes contained a greater percentage of cells with higher
forward scatter and lower side scatter, which is typical of live cells.
This was observed for both the CD16
2 and CD16
+ monocytes.
To determine whether the viability of monocyte subsets was
indeed increased upon virus exposure, we stained the cells with
Annexin V and 7-AAD over the course of 6 days (Fig. 4 B & C).
There were significantly more viable cells (AnnexinV
-7-AAD
-) for
both monocyte subsets following exposure to virus compared to
monocytes without virus. Fig. 4 B shows a representative dot plot
of unexposed and virus exposed monocyte subsets at day 2. Fig. 4
C represents accumulated data for AnnexinV
- 7-AAD
- cells over
the course of 6 days. We also used a Live/Dead cell stain kit that
consists of a dye that emits at 660 nm to determine viability. Live
cells actively exclude this dye and stain dimly, while dead cells are
unable to exclude the dye and stain brightly. The percentages of
viable (dimly stained) and dead cells (brightly stained) in virus
exposed or monocyte subsets without virus were determined by
flow cytometry (Fig. 4 D, E). The results showed that the
percentage of viable cells after virus exposure was significantly
higher (,2 fold) for both monocyte subsets. Finally we used a non-
flow cytometry based approach to test cell viability. The MTS
assay utilizes the dehydrogenase activity of viable cells to convert
MTS into a substrate that absorbs at OD490 nm. Absorbance at
OD490 nm is proportional to the number of viable cells in culture.
For each monocyte subset, the absorbance for virus exposed cells
was normalized to monocytes without virus. The results at day 2
showed that absorbance was approximately 1.5 times higher in
monocyte cultures with virus (Fig. 4 F). These data show that the
viability of both monocyte subsets was similarly enhanced by
exposure to dengue virus. Hence, exposure of monocytes to
dengue virus could have down-regulated spontaneous apoptosis
that occurs normally in non-stimulated monocytes [45247]. The
increased viability of monocyte subsets through dengue virus
exposure may serve to enhance the functions of monocytes during
dengue virus infection, for example through sustaining their ability
to produce cytokines.
IL-4 Pretreatment of Monocyte Subsets Enhances the
Susceptibility of CD16
+ Monocyte Subsets to a Greater
Extent
It has been previously shown that pre-treatment of human
monocytes with IL-4 or IL-13, increases their susceptibility to
dengue virus infection in vitro [37]. We further investigated if IL-4
treatment of the two monocyte subsets differentially affects their
susceptibility to dengue virus infection. For this, CD16
+ and
CD16
2 monocyte subsets were cultured with IL-4 for two days
before exposure to dengue virus. The extent of infection was
measured using intracellular staining for NS1 and 4G2 over the
course of 6 days after initial exposure (Fig. 5 A & B). IL-4
treatment of both monocyte subsets results in significantly
increased percentage of infected cells, as compared to the
respective monocyte subset control without IL-4 treatment.
However, we observed particularly for day 1 after infection, the
extent of NS1 and 4G2 percentage positive cells was significantly
greater for IL-4 treated CD16
+ monocytes as compared to CD16-
monocytes. This result suggests that CD16
+ monocytes became
more susceptible than CD16
2 monocytes after IL-4 treatment.
The preferential susceptibility of the CD16
+ monocytes after IL-4
treatment was also supported by the results of the plague assay,
which show that the supernatants of the IL-4 treated CD16
+
monocyte subset harbored a higher titer of dengue virus compared
to the IL-4 CD16
2 treated monocyte subset (Fig. 5 C).
Discussion
Monocytes play a central role in dengue infection, but the
relative role of monocyte subsets during dengue infection is
unclear. We find that freshly isolated healthy monocyte subsets
were equally susceptible to dengue virus infection, indicating that
at least during normal physiological conditions, dengue virus
infection is not preferentially biased towards either subset. We also
show that monocyte subsets were equally capable of producing
anti-viral factors associated with dengue protection, such as IFN-a,
CXCL10 and TRAIL. This demonstrates that both monocyte
subsets can potentially contribute to anti-dengue responses
through multiple mechanisms. Type 1 interferons like IFN-a are
potent anti-virals that limit the propagation of dengue virus
[42,43]. CXCL10 competes with dengue virus for binding to cell
surface heparan sulfate, thereby reducing viral uptake and
infection of cells [40,41]. Interestingly, CXCL10 is the ligand for
CXCR3, expressed by NK cells and T helper type 1 cells [48,49].
Though speculative, the production of CXCL10 by monocytes
could also be a mechanism for the efficient recruitment and
activation of these cells during dengue infection, thereby positively
influencing disease outcome in two ways. TRAIL has been
identified as a protective factor against dengue infection [44] via a
mechanism linked to type 1 interferon responses [50].
CD16
+ monocytes are known for their preferential ability to
produce inflammatory cytokines after stimulation [51,52]. Con-
sistent with this, CD16
+ monocytes dominated the production of
inflammatory cytokines in response to dengue virus infection.
Unregulated production of inflammatory cytokines could contrib-
ute to the immune pathogenesis of dengue, such as vascular
leakage, which is a hallmark of severe forms of the disease [18,27].
For example, TNF-a can mediate vascular leakage by increasing
the permeability of endothelial cell monolayers [53,54]. Further-
more, higher serum levels of inflammatory cytokines are associated
with severe dengue [55257]. Hence, it is possible that CD16
+
monocytes contribute to immune pathogenesis through inflam-
matory mechanisms. However, the production of TNF-a and IL-
1b was early and transient in our experiments. The severe dengue
symptoms like vascular leakage, which usually occur in the later
stages of infection, could be the consequence of continuous
differentiation or release of CD16
+ monocytes into the circulation.
CCL chemokines, in particular CCL2, 3 and 4 were preferen-
tially produced by CD16
+ monocytes during the early phases of
the dengue response in our assays. This may be involved in the
recruitment of other immune cells by CD16
+ monocytes, which
could be a protective mechanism to accumulate other immune
cells in lymphatic tissue or infected organs during dengue
infection. CCL2 is potentially involved in mediating vascular
Monocyte Subsets and Dengue
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endothelial cells and enhances vascular permeability [58]. CCL2 is
also present at higher levels in the serum of dengue hemorrhagic
fever patients compared to dengue fever patients [58]. The levels
of CCL2 produced by CD16
+ monocytes were relatively constant
over time, and might represent a possible mechanism by which
CD16
+ monocytes could mediate vascular leakage in the later
phases of the dengue infection. In contrast to CCL2, CCL4 levels
have been associated with a good prognosis in dengue infection
[59], perhaps through an association with numbers of circulating
CD56
+ NK cells.
Monocytes are known to die spontaneously by apoptosis and
this can be prevented with appropriate stimuli [60262]. Our study
showed that the exposure of monocyte subsets to dengue virus
prevented the spontaneous apoptosis that occurred in non-
stimulated monocytes. Increased viability of infected cells could
have important implications in vivo, resulting in prolonged cytokine
and chemokine production. Interestingly, it has been found that
for epithelial cells, flavivirus NS4A protein induces autophagy and
Figure 4. Viability of monocyte subsets after dengue virus exposure. (A) Representative forward scatter (FSC) versus side scatter (SSC) plot
of monocyte subsets exposed to dengue virus or medium without virus after 2 days. Numbers indicate percentages within each region gate. (B)
Annexin V and 7-AAD staining of monocyte subsets exposed to dengue virus or medium without virus after 2 days. Representative data for 5
different donors. (C) Percentage of viable monocyte subsets (Annexin V and 7-AAD double negative) over the course of 6 days after exposure to
dengue virus or medium without virus. Data are expressed as mean 6 SE from 5 different donors. (D) Live/Dead staining of monocyte subsets
exposed to dengue virus or medium without virus after 2 days. Dead cells stain strongly with the dye (right peaks) while live cells are able to actively
exclude the dye and are thus stained weakly (left peaks). Representative data for 4 different donors. (E) Percentage of live cells exposed to dengue
virus or medium without virus after 2 days. Data are expressed as mean 6 SE from 4 different donors. (F) MTS assay. Metabolic activity of live cells
produces a substrate that absorbs at OD490 nm. Absorbance at OD490 nm is proportional to the number of live cells. Data are normalized to the
respective monocyte subset without virus. Representative data for 2 different donors. *, p,0.05 between respective monocyte subset with and
without virus.
doi:10.1371/journal.pone.0036435.g004
Figure 5. IL-4 treatment enhances the susceptibility of the CD16
+ monocyte subset to a greater extent. Isolated CD16
2 or CD16
+
monocyte subsets were pretreated with 25 ng/ml of IL-4 for two days. Cells were subsequently washed and harvested before exposure to dengue
virus (DENV2, NGC) at a MOI of 10 or medium without virus. Percentages of CD16
2 and CD16
+ monocytes that are (A) NS1
+ or (B) E-protein
+ over the
course of 6 days after virus exposure. Results are mean 6 SE of 5 different donors. (C) Plaque assays with BHK-21 cells were performed with
supernatants taken from virus exposed IL-4 treated CD16
2 or CD16
+ monocytes over the course of 6 days. Results are mean 6 SE from 4 different
donors. * p,0.05, between IL-4 treated CD16
+ and IL-4 treated CD16
2 monocytes with virus.
doi:10.1371/journal.pone.0036435.g005
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enhanced viability and prolonged survival of infected monocytes
needs to be verified in dengue patients.
Th2 cytokines have been known to enhance the susceptibility of
primary human monocytes [37]. Here, we extend these results by
showing that IL-4 pre-treatment affects the susceptibility of the
CD16
+ monocyte subset to a greater extent. These results may
imply that the CD16
+ monocyte subset may have a bigger
contribution to dengue virus pathogenesis during Th2-biased
immune responses.
While there are concerns over whether positive selection could
have non-specifically activated or perturb the behavior of the
monocyte subsets, a microarray study comparing positive and
negative selected peripheral blood mononuclear cell (PBMCs)
populations reveal that positive selection did not affect cellular
transcription in any significant manner [64]. Negative selection
was deemed inferior due to lower cell purities which resulted in
significant changes to the transcriptome. While there is also a
concern that the 10% contaminating cells could have contributed
to the results of the study, our preliminary results and those of Kou
et al [26] shows that monocytes and not other PBMCs were
infected by dengue virus (Fig S1A & B). Furthermore, as CD16
was found to be spontaneously upregulated during culture even
without virus (Fig S1C), it was not possible to analyze the infection
of monocyte subpopulations without isolating them first. Never-
theless, after infection of whole PBMCs for two days, a small
population of CD14+CD16- monocytes could still be observed. By
gating on these CD14+CD16- and CD14+CD16+ monocytes, we
could see that the infection rates were similar (figure S1D, E & F).
Hence, this further supports the notion that prior isolation of
monocyte subsets does not affect their susceptibility to dengue
virus infection. Furthermore, we found little NS1 and 4G2
expression by CD14- non-monocytes. Hence, the contaminating
10% of non-monocytes in PBMCs are unlikely to contribute to the
results obtained in this study. The average percentage of NS1 and
4G2 and standard deviation for the various populations analysed
for all three donors are also shown in Fig 1F.
There might also be concerns on whether the results obtained
from the lab adapted NGC strain is best suited for infecting
primary cells. However, other groups have also successfully
infected human monocytes using the 16681 strain, and have
found comparable results between the 16681 and NGC strain
[26,65], this suggests that the results obtained for NGC can also be
applicable to a broader range of DENV-2 virus strains.
Overall, our results delineate how monocyte subsets can have
both similar and different responses to dengue virus infection. This
demonstrates the advantage of taking monocyte heterogeneity into
account for studies of viral infections like dengue. More recently,
monocytes have been further subdivided into three subsets
[66268]. Future studies on the individual roles of these subsets
may reveal further insights into the contribution of monocyte
subsets to viral diseases like dengue. For example, it was shown
that amongst the CD16
+ monocyte subset, the CD14
high
intermediate subset was selectively expanded in mild but not
severe dengue [65]. Furthermore, monocytes are known to be
involved in secondary infections that result in antibody dependent
enhancement and severe dengue disease. It will be of great interest
to determine the relative contribition of monocyte subsets to
secondary dengue virus infections. We believe that these endeavors
would allow the identification and development of more precise
therapeutic strategies for dengue.
Supporting Information
Figure S1 Infection of whole PBMCs. Whole 1 PBMCs
were were exposed to dengue virus or medium without virus. After
two days, surface staining of CD14 and CD16, and intracellular
staining for NS1 and 4G2 was performed. (A) NS1 and 4G2
expression by gating on the whole CD14
+ monocyte population.
(B) NS1 and 4G2 expression by gating on the whole CD14
2 non
monocyte population. (C) CD14 and CD16 profiles demonstrating
the spontaneous upregulation of CD16 by monocytes after two
days of culture. (D) NS1 and 4G2 expression by gating on the
CD14
+CD16
+ monocyte population (E) NS1 and 4G2 expression
by gating on the CD14
+CD16 monocyte population. (F)
Percentage of NS1
+ and 4G2 positive cells from the mean + SD
of three donors.
(PDF)
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